Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 3/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | PRKDC | P78527 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | ACLY | P53396 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
| ▸ | BACE1 | P56817 | 3/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.30 |
| ▸ | HPGD | P15428 | 2/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16268750 | 0.86 | ERN1 (0.36) | ERN1LMNAPRKDCALDH1A1CYP2C19 | |
| SCHEMBL16269517 | 0.84 | LMNA (0.51) | ERN1LMNAALDH1A1CYP2C19CYP1A2 | |
| SCHEMBL1630491 | 0.82 | ERN1 (0.50) | ERN1LMNAPRKDCALDH1A1CYP2C19 | |
| Ammonia Solution, Strong SCHEMBL16268999 | 0.80 | ERN1 (0.49) | ERN1LMNAPRKDCALDH1A1CYP2C19 | |
| SCHEMBL29303386 | 0.80 | AAK1 (0.36) | ERN1LMNAPRKDCALDH1A1CYP2C19 | |
| SCHEMBL25340829 | 0.78 | KDM1A (0.35) | CYP2C19ACLYCYP3A4CYP2D6TSHR | |
| SCHEMBL29509739 | 0.78 | KDM1A (0.35) | CYP2C19ACLYCYP3A4CYP2D6TSHR | |
| SCHEMBL16269289 | 0.78 | ALDH1A1 (0.39) | ERN1LMNAALDH1A1CYP1A2CYP2C9 | |
| SCHEMBL28924967 | 0.77 | ERN1 (0.36) | ERN1LMNAPRKDCALDH1A1CYP2C19 | |
| SCHEMBL17441687 | 0.76 | NPC1 (0.47) | ERN1LMNAALDH1A1MAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3494118-B1 | NITROGEN-CONTAINING TRICYCLIC COMPOUNDS AND USES THEREOF IN MEDICINE | SUNSHINE LAKE PHARMA CO LTD (CN) | 2023-06-21 | — | — | EP | disclosed |
| CN-107686486-B | Nitrogenous tricyclic compound and application thereof in medicine | 广东东阳光药业有限公司 | 2020-12-22 | — | — | CN | disclosed |
| US-10562910-B2 | Nitrogen-containing tricyclic compounds and uses thereof in medicine | NORTH & SOUTH BROTHER PHARMACY INVESTMENT COMPANY LIMITED (HK) | 2020-02-18 | — | — | US | disclosed |
| US-20190169203-A1 | NITROGEN-CONTAINING TRICYCLIC COMPOUNDS AND USES THEREOF IN MEDICINE | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2019-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10562910-B2 | Nitrogen-containing tricyclic compounds and uses thereof in medicine | NR1H4, SLC10A1, SLC10A2 | ERN1 2220/4885LMNA 2905/4885PRKDC 3100/4885 |
| US-20190169203-A1 | NITROGEN-CONTAINING TRICYCLIC COMPOUNDS AND USES THEREOF IN MEDICINE | NR1H4, SLC10A1, SLC10A2 | ERN1 2220/4885LMNA 2905/4885PRKDC 3100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.